Webinar | A pioneering CAR-T therapy targeting mutated calreticulin in myeloproliferative neoplasms (MPN)
- Global Mpn Scientific Foundation
- 14 hours ago
- 2 min read
On February 4th at 7:00 pm (Madrid time), coinciding with World Cancer Day, an online webinar will take place focusing on an innovative line of research in myeloproliferative neoplasms (MPN): the development of a CAR-T therapy targeting mutated calreticulin (mCALR). This webinar is organised by MPN Spain.
📅 Date: February 4, 2026
⏰ Time: 7:00 pm (CET – Madrid time)
💻 Format: Online webinar via Zoom
This session aims to bring research closer to patients and families, explaining in a clear and accessible way how scientific advances may become future therapeutic options. The webinar will also be available in English, thanks to the support of the Global MPN Scientific Foundation.
Webinar topics
During the session, the following topics will be covered:
What Philadelphia-negative MPN are (essential thrombocythemia, polycythemia vera and myelofibrosis).
Why mutated calreticulin (CALR) is a key target for new therapies.
The development of a pioneering CAR-T therapy and the main preclinical results.
The current status and design of the first clinical trial in humans.
Speakers
The webinar will feature:
Dr. Maite Olave, Head of Hematology, Hospital Clínico de Zaragoza, and principal investigator of the clinical trial.
Cecilia Pesini, researcher at the Aragón Health Research Institute (IIS Aragón), who will present the preclinical research conducted to date and ongoing work. This research forms part of her doctoral thesis within Dr. Ariel Ramírez Labrada’s team.
Dr. María del Mar Mole, hematologist at Hospital Clínico de Zaragoza, who will explain the design of the clinical trial and its preparation for submission to the Spanish Agency of Medicines and Medical Devices (AEMPS).
Dr. Ariel Ramírez Labrada, researcher at IIS Aragón, who will take part in the Q&A session.